- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01256151
Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet
January 26, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open-label, Randomized, Single-Dose, 2 Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet
To assess if the sublingual tablet will have similar pharmacokinetics as the conventional tablet of alprazolam.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.
- Signed informed consent.
Exclusion Criteria:
- Evidence or history of clinically significant abnormalities
- Positive drug screen, excessive alcohol and tobacco use
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Alprazolam conventional tablet
|
1 mg single dose of alprazolam conventional tablet
|
Experimental: Alprazolam sublingual tablet
|
1 mg single dose of alprazolam sublingual tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve (AUC) from time zero to last measurable time of alprazolam
Time Frame: 72 hours
|
72 hours
|
Peak concentration of alprazolam
Time Frame: 72 hours
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the curve from time zero to infinity
Time Frame: 72 hours
|
72 hours
|
AUC% extrapolated
Time Frame: 72 hours
|
72 hours
|
Time of Cmax
Time Frame: 72 hours
|
72 hours
|
half-life of alprazolam
Time Frame: 72 hours
|
72 hours
|
Clinically significant safety laboratory tests
Time Frame: Screening, Day 0, Day 4
|
Screening, Day 0, Day 4
|
Clincally significant vital signs
Time Frame: Screening, Day 4
|
Screening, Day 4
|
Clinically significant adverse events
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
December 6, 2010
First Submitted That Met QC Criteria
December 6, 2010
First Posted (Estimate)
December 8, 2010
Study Record Updates
Last Update Posted (Actual)
January 28, 2021
Last Update Submitted That Met QC Criteria
January 26, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A6131024
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety Disorder
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
University of MichiganBrain & Behavior Research FoundationNot yet recruitingGeneralized Anxiety Disorder | Anxiety | Social Anxiety Disorder | Panic DisorderUnited States
-
Baylor College of MedicineUniversity of PennsylvaniaRecruitingGeneralized Anxiety Disorder | Anxiety | Autism Spectrum Disorder | Separation Anxiety | Social Anxiety Disorder of ChildhoodUnited States
-
Erasmus Medical CenterTerminatedGeneralized Anxiety Disorder | Social Anxiety Disorder | Specific Phobia | Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood, Early OnsetNetherlands
-
Baylor College of MedicineRecruitingGeneralized Anxiety Disorder | Panic Disorder | Panic Disorder With Agoraphobia | Separation Anxiety | Anxiety Disorder of Childhood | Panic Attacks | Social Anxiety Disorder of Childhood | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Daniel LiebermanTerminatedAnxiety | Anxiety Disorder SocialUnited States
-
Hospital de Clinicas de Porto AlegreUnknownGeneralized Anxiety Disorder | Social Anxiety Disorder | Separation Anxiety DisorderUnited States, Australia, Brazil, Israel
-
UCLH/UCL Joint Research OfficeMedical Research Council; Camden and Islington NHS Trust; Central and North West...RecruitingAnxiety Disorders | Anxiety | Anxiety Depression | CBT | Anxiety Disorders and Symptoms | Anxiety Generalized | Generalised Anxiety Disorder | Anxiety Disorder; Mixed With Depression (Mild) | Anxiety Disorder GeneralizedUnited Kingdom
-
State University of New York - Upstate Medical...CompletedGeneral Anxiety Disorder, Social Anxiety DisorderUnited States
-
Haukeland University HospitalUniversity of BergenCompletedGeneralized Anxiety Disorder | Social Anxiety Disorder | Separation Anxiety DisorderNorway
Clinical Trials on Alprazolam tablet
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Withdrawn
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Withdrawn
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Withdrawn
-
GlaxoSmithKlineCompleted
-
Alexza Pharmaceuticals, Inc.Completed
-
Universitair Ziekenhuis BrusselUnknownCoronary Angiography | Sedative PremedicationBelgium
-
Alexza Pharmaceuticals, Inc.The Epilepsy Study ConsortiumCompleted
-
UCB Biopharma SRLCompletedHealthy ParticipantsUnited States